Maravai LifeSciences (NASDAQ:MRVI) Sees Large Volume Increase – Still a Buy?

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw unusually-strong trading volume on Thursday . Approximately 2,318,486 shares traded hands during mid-day trading, an increase of 4% from the previous session’s volume of 2,227,500 shares.The stock last traded at $7.9750 and had previously closed at $7.22.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MRVI shares. Weiss Ratings raised shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Wall Street Zen raised Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $6.00 target price on shares of Maravai LifeSciences in a report on Friday, May 8th. Wells Fargo & Company lifted their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.25.

Maravai LifeSciences Trading Up 12.2%

The firm has a 50-day moving average price of $6.15 and a 200-day moving average price of $4.51. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. The stock has a market cap of $2.10 billion, a PE ratio of -15.58 and a beta of 0.63.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. As a group, equities analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year.

Insider Buying and Selling

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the sale, the general counsel directly owned 360,767 shares in the company, valued at approximately $1,825,481.02. This trade represents a 6.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors have recently modified their holdings of the business. Royal Bank of Canada raised its position in Maravai LifeSciences by 49.0% in the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after buying an additional 3,209 shares during the last quarter. Quantessence Capital LLC purchased a new stake in shares of Maravai LifeSciences during the 3rd quarter valued at about $31,000. Abel Hall LLC purchased a new stake in shares of Maravai LifeSciences during the 3rd quarter valued at about $33,000. CIBC Bancorp USA Inc. bought a new stake in shares of Maravai LifeSciences in the third quarter worth approximately $33,000. Finally, Virtu Financial LLC purchased a new position in shares of Maravai LifeSciences during the fourth quarter valued at approximately $34,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.